Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 2

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 73NET 22Thoracic 10Gastrointestinal 10Lymphoid 5Sarcoma 4Dermatologic 4Other solid neoplasm 2Head & Neck 2Gynecologic 2CNS 2Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 412Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 83Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 55Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Carcinoma, Non-Small-Cell Lung 45Neoplasm Metastasis 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Prostatic Neoplasms 29Vaginal Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Small Cell Lung Carcinoma 22Urinary Bladder Neoplasms 21

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Neuroendocrine × Gynecologic × Clear all
NCT05337735 2026-05-04

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

M.D. Anderson Cancer Center

Phase 2 Suspended
140 enrolled
EndocrineGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Hodgkin Disease, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03012620 2024-02-28

AcSé

UNICANCER

Phase 2 Completed
334 enrolled
CNSEndocrineGynecologicHead & NeckLymphoidSarcoma

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡